Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹85 Cr
Revenue (TTM)
₹515 Cr
Net Profit (TTM)
₹283 Cr
ROE
0 %
ROCE
26 %
P/E Ratio
0.3
P/B Ratio
-0.2
Industry P/E
44.74
EV/EBITDA
12.6
Div. Yield
0 %
Debt to Equity
-2.1
Book Value
₹--
EPS
₹2.9
Face value
2
Shares outstanding
54,164,653
CFO
₹270.68 Cr
EBITDA
₹-74.64 Cr
Net Profit
₹-783.96 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift
| -52.3 | -5.0 | 21.9 | -36.5 | 16.6 | 40.8 | 11.6 |
|
BSE Healthcare*
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift
| 83.6 | 43.9 | -0.4 | 226.7 | 26.2 | -54.5 | -38.4 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
2 min read•By Value Research
2 min read•By Research Desk
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective,... cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name. In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology. Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services. The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia. Swift Limited was founded in 1983 and is based in Chandigarh, India. Read more
Incorporated
1986
Chairman
S R Mehta
Managing Director
Gopal Munjal
Headquarters
Chandigarh, Union Territory
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Ind-Swift Ltd is ₹15.76 (NSE) and ₹15.70 (BSE) as of 13-Aug-2025 IST. Ind-Swift Ltd has given a return of 16.57% in the last 3 years.
The P/E ratio of Ind-Swift Ltd is 0.30 times as on 13-Aug-2025, a 99 discount to its peers’ median range of 44.74 times.
The P/B ratio of Ind-Swift Ltd is -0.21 times as on 13-Aug-2025, a 107 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
6.97
|
-0.14
|
|
2023
|
1.50
|
-0.06
|
|
2022
|
0.00
|
-0.08
|
|
2021
|
0.00
|
-0.04
|
|
2020
|
0.00
|
-0.02
|
The 52-week high and low of Ind-Swift Ltd are Rs 34.70 and Rs 12.00 as of 05-Apr-2026.
Ind-Swift Ltd has a market capitalisation of ₹ 85 Cr as on 13-Aug-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Ind-Swift Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.91
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.